

Michele Milella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4228020/publications.pdf>

Version: 2024-02-01

187
papers

13,463
citations

61857

43
h-index

24179

110
g-index

188
all docs

188
docs citations

188
times ranked

19251
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
2	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	5.1	1,034
3	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	0.8	509
4	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
5	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
6	PTEN: Multiple Functions in Human Malignant Tumors. <i>Frontiers in Oncology</i> , 2015, 5, 24.	1.3	356
7	Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. <i>Cancer Research</i> , 2006, 66, 5549-5554.	0.4	314
8	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	0.8	279
9	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
10	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	0.8	244
11	The mTOR Pathway: A New Target in Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2010, 10, 484-495.	0.8	152
12	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. <i>Leukemia</i> , 2012, 26, 778-787.	3.3	126
13	Circulating Autoantibodies to Phosphorylated β -Enolase are a Hallmark of Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 105-112.	1.8	119
14	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2453.	1.8	109
15	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , 2018, 10, 23.	1.7	108
16	Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. <i>Cell Death and Disease</i> , 2019, 10, 201.	2.7	105
17	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , 2015, 26, 542-547.	0.6	96
18	Molecular Tumor Boards in Clinical Practice. <i>Trends in Cancer</i> , 2020, 6, 738-744.	3.8	94

#	ARTICLE	IF	CITATIONS
19	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 2277-2285.	0.6	86
20	PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?. <i>Cancers</i> , 2019, 11, 435.	1.7	86
21	Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?. <i>Oncologist</i> , 2020, 25, e555-e569.	1.9	86
22	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. <i>Advances in Biological Regulation</i> , 2014, 56, 66-80.	1.4	77
23	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. <i>European Journal of Cancer</i> , 2013, 49, 3609-3615.	1.3	76
24	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
25	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , 2019, 11, 1141.	1.7	71
26	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014, 110, 2165-2169.	2.9	69
27	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
28	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	1.3	60
29	Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. <i>Cell Discovery</i> , 2017, 3, 17022.	3.1	59
30	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.2	58
31	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 12783-12795.	0.8	58
32	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. <i>World Journal of Gastroenterology</i> , 2015, 21, 4788.	1.4	56
33	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 906-911.	0.9	55
34	Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. <i>Current Pharmaceutical Design</i> , 2014, 20, 3944-3957.	0.9	55
35	Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 203-223.	1.0	54
36	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	1.7	54

#	ARTICLE	IF	CITATIONS
37	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 156.	3.5	54
38	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. <i>Molecular Cancer</i> , 2014, 13, 230.	7.9	51
39	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 275.	1.7	50
40	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	1.7	49
41	KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 227.	3.5	49
42	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>Oncotarget</i> , 2016, 7, 11332-11348.	0.8	49
43	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 1183-1196.	1.5	48
44	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , 2018, 39, 971-980.	1.3	48
45	Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5351.	1.2	47
46	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 58.	3.5	46
47	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 309-315.	1.1	44
48	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	1.6	44
49	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67.	6.9	42
50	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. <i>Cell Death and Disease</i> , 2015, 6, e1850-e1850.	2.7	42
51	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 638360.	1.3	42
52	Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. <i>Scientific Reports</i> , 2017, 7, 13024.	1.6	39
53	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
54	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for a lateral combination strategies. <i>Journal of Molecular Medicine</i> , 2012, 90, 1133-1144.	1.7	35
56	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , 2020, 52, 297-309.	0.3	35
57	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , 2019, 11, 1152.	1.7	33
58	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2014, 15, 411-417.e4.	1.1	32
59	Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , 2014, 5, 11054-11063.	0.8	32
60	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , 2014, 10, 2141-2147.	1.1	30
61	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	0.9	30
62	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	0.9	30
63	Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies. <i>Oncology</i> , 2010, 78, 141-149.	0.9	29
64	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 54.	3.5	29
65	EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 672-680.	0.5	28
66	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019, 11, 1525.	1.7	28
67	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8841.	1.8	28
68	Biology of Metastatic Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2011, 2, 369-373.	1.2	27
69	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 115.	3.5	27
70	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 3316-3327.	3.2	27
71	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 140.	3.5	27
72	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. <i>Scientific Reports</i> , 2019, 9, 12286.	1.6	27

#	ARTICLE	IF	CITATIONS
73	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5337.	1.8	26
74	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 650293.	1.3	26
75	Maintenance therapy in NSCLC: why? To whom? Which agent?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 50.	3.5	24
76	Molecular and Genetic Bases of Pancreatic Cancer. <i>Current Drug Targets</i> , 2012, 13, 731-743.	1.0	24
77	Prognostic factors in gemcitabine+ cisplatin polychemotherapy regimens in pancreatic cancer: XPD Lys751Gln polymorphism strikes back. <i>International Journal of Cancer</i> , 2013, 133, 1016-1022.	2.3	23
78	The pattern of hMENA isoforms is regulated by TGF- β 1 in pancreatic cancer and may predict patient outcome. <i>Onc Immunology</i> , 2016, 5, e1221556.	2.1	23
79	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , 2020, 9, 309.	1.8	23
80	Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. <i>Current Medicinal Chemistry</i> , 2017, 24, 1383-1402.	1.2	23
81	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.	1.3	22
82	Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 471-476.	0.9	22
83	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
84	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	2.0	21
85	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 169-185.	1.5	21
86	Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	20
87	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5325-5334.	0.7	20
88	Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. <i>European Journal of Cancer</i> , 2020, 135, 159-169.	1.3	20
89	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). <i>Cancers</i> , 2020, 12, 1681.	1.7	20
90	Infections and Immunotherapy in Lung Cancer: A Bad Relationship?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 42.	1.8	20

#	ARTICLE	IF	CITATIONS
91	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 278.	3.5	19
92	Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 66.	3.5	18
93	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. <i>BMC Cancer</i> , 2010, 10, 675.	1.1	18
94	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 91.	3.5	18
95	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1341-1348.	0.5	18
96	Thymosin alpha α 1 with peginterferon alfa α 2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 52-59.	1.0	17
97	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 568-575.	0.5	17
98	Renal cancer: new models and approach for personalizing therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 217.	3.5	17
99	Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A "Hard Days Night". <i>Current Pharmaceutical Design</i> , 2014, 20, 3958-3972.	0.9	17
100	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103571.	2.0	17
101	Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. <i>Clinical Oncology</i> , 2021, 33, e31-e38.	0.6	16
102	A multimodal approach to cancer-related cachexia: from theory to practice. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 819-826.	1.1	16
103	Exercise prehabilitation in lung cancer: Getting stronger to recover faster. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1847-1855.	0.5	16
104	Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. <i>Thrombosis Research</i> , 2020, 194, 216-219.	0.8	15
105	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 50-59.	2.0	14
106	Muscle derangement and alteration of the nutritional machinery in NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 43-53.	2.0	14
107	Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1579-1590.	1.8	14
108	Sequential therapy in metastatic clear cell renal carcinoma: TKI vs TKI + mTOR. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1545-1557.	1.1	13

#	ARTICLE	IF	CITATIONS
109	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, 2896-2898.	0.6	13
110	Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar. <i>Frontiers in Oncology</i> , 2020, 10, 600940.	1.3	13
111	Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling. <i>Genes</i> , 2021, 12, 481.	1.0	13
112	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 4511.	1.4	13
113	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 697-709.	1.1	12
114	“Running with cancer”: A qualitative study to evaluate barriers and motivations in running for female oncological patients. <i>PLoS ONE</i> , 2020, 15, e0227846.	1.1	12
115	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
116	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.2	11
117	Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa071.	1.4	11
118	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , 2020, 5, e000689.	2.0	11
119	Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. <i>Cell Death and Disease</i> , 2012, 3, e440-e440.	2.7	10
120	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. <i>Pharmacogenomics</i> , 2014, 15, 609-618.	0.6	10
121	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015, 11, 3159-3166.	1.1	10
122	Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 109-114.	1.1	10
123	Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1507-1511.	1.3	10
124	Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 885-903.	0.8	10
125	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 148.	3.5	10
126	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	2.0	9

#	ARTICLE	IF	CITATIONS
127	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 435-446.	0.7	9
128	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094796.	1.4	9
129	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	1.1	9
130	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. <i>Anti-Cancer Drugs</i> , 2010, 21, 459-464.	0.7	8
131	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. <i>Digestive and Liver Disease</i> , 2011, 43, 225-230.	0.4	8
132	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.3	8
133	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. <i>Clinical Lung Cancer</i> , 2019, 20, e514-e516.	1.1	8
134	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , 2020, 10, 588862.	1.3	8
135	BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , 2020, 3, 546.	2.0	8
136	Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it. <i>ESMO Open</i> , 2021, 6, 100095.	2.0	8
137	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , 2021, 60, 6-14.	0.9	8
138	Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?. <i>Updates in Surgery</i> , 2020, 72, 321-324.	0.9	8
139	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. <i>Oncotarget</i> , 2017, 8, 108463-108479.	0.8	8
140	Early recurrence risk: aromatase inhibitors versus tamoxifen. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1239-1253.	1.1	7
141	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 662205.	1.3	7
142	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 351-360.	1.1	7
143	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 688889.	1.3	7
144	Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. <i>Pancreatology</i> , 2021, 21, 1038-1047.	0.5	7

#	ARTICLE	IF	CITATIONS
145	Exercise and anemia in cancer patients: could it make the difference?. <i>Expert Review of Hematology</i> , 2021, 14, 979-985.	1.0	7
146	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1381-1397.	2.5	6
147	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 597-608.	0.9	6
148	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1143-1161.	1.9	6
149	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. <i>Cancers</i> , 2020, 12, 1131.	1.7	6
150	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 531-542.	1.1	6
151	Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface. <i>ESMO Open</i> , 2021, 6, 100028.	2.0	6
152	ICGC-ARGO precision medicine: familial matters in pancreatic cancer. <i>Lancet Oncology</i> , The, 2022, 23, 25-26.	5.1	6
153	Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. <i>Future Science OA</i> , 2021, 7, FSO659.	0.9	5
154	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. <i>ESMO Open</i> , 2022, 7, 100308.	2.0	5
155	Exercise oncology: It is time to make a change. <i>Patient Education and Counseling</i> , 2022, 105, 2629-2631.	1.0	5
156	Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 1-4.	1.5	5
157	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. <i>Nutrition</i> , 2022, 98, 111637.	1.1	5
158	Optimizing clinical benefit with targeted treatment in mRCC: "Tumor growth rate" as an alternative clinical endpoint. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 73-81.	2.0	4
159	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S266-S267.	0.5	4
160	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019, 134, 121-126.	0.9	4
161	Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction. <i>Clinical Lung Cancer</i> , 2021, ...	1.1	4
162	Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. <i>Immunotherapy</i> , 2021, 13, 971-976.	1.0	4

#	ARTICLE	IF	CITATIONS
163	Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability. <i>Journal of Cancer Education</i> , 2023, 38, 42-49.	0.6	4
164	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. <i>Cells</i> , 2021, 10, 2685.	1.8	4
165	Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research. <i>European Journal of Oncology Nursing</i> , 2021, 55, 102061.	0.9	4
166	Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance. <i>Biomedicines</i> , 2022, 10, 277.	1.4	4
167	Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy?. <i>Acta Oncologica</i> , 2022, 61, 388-392.	0.8	4
168	Long-term survivors with immunotherapy in advanced NSCLC: is "cure"™ within reach?. <i>Translational Cancer Research</i> , 2020, 9, 409-414.	0.4	3
169	Phase III study (daNIS-2) of the anti-TGF- β 2 monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4193-TPS4193.	0.8	3
170	Editorial (Thematic Issue: The Lung and Winding Road: Twists and Turns on the Way to Personalized) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.9	2
171	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , 2014, 25, 2443-2444.	0.6	2
172	A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. <i>BMC Cancer</i> , 2021, 21, 165.	1.1	2
173	Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 672219.	2.2	2
174	Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona. <i>Annals of Oncology</i> , 2022, 33, 661-663.	0.6	2
175	Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-11.	1.1	2
176	Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
177	Lost in translation: bridging the gap between cancer research and effective therapies. <i>Cell Death and Differentiation</i> , 2011, 18, 1082-1084.	5.0	1
178	ASO Author Reflections: Preoperative Nutritional Care: The "Cinderella"™ of Surgical Management in Patients with Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 5335-5336.	0.7	1
179	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16769-e16769.	0.8	1
180	Treatment and Outcome(S) of a Large Cohort of Poor Risk Metastatic Renal Cell Carcinoma (Prrcc) Patients (Pts). <i>Annals of Oncology</i> , 2014, 25, iv290.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.. Journal of Clinical Oncology, 2020, 38, 12056-12056.	0.8	0
182	Title is missing!., 2020, 15, e0227846.		0
183	Title is missing!., 2020, 15, e0227846.		0
184	Title is missing!., 2020, 15, e0227846.		0
185	Title is missing!., 2020, 15, e0227846.		0
186	The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (I ¹⁷ -Meet-URO analysis).. Journal of Clinical Oncology, 2022, 40, 4534-4534.	0.8	0
187	Phase II study (daNIS-1) of the anti-TGF- β 2 monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology, 2022, 40, TPS4183-TPS4183.	0.8	0